Advanced search
Publication Cover
Clinical Ophthalmology Volume 13, 2019 - Issue
Submit an article Journal homepage
114
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation

Eduardo Chávez-Mondragón1 Fundación de Asistencia Privada Conde de Valenciana, IAP, CDMX, MexicoORCID Iconhttps://orcid.org/0000-0002-3665-0254
ORCID Icon,
Claudia Palacio2 Fundación Hospital Nuestra Señora de la Luz, IAP, CDMX, Mexico
,
Abraham Soto-Gómez3 Catarata y Glaucoma de Occidente, SA de CV, Guadalajara, Jalisco, MexicoORCID Iconhttps://orcid.org/0000-0003-3588-1322
ORCID Icon,
Miguel Villanueva-Nájera4 Private Office, CDMX, MexicoORCID Iconhttps://orcid.org/0000-0001-6324-4748
ORCID Icon,
Guillermo De Wit-Carter5 Asociación para Evitar la Ceguera en Mexico IAP, CDMX, Mexico
,
Ruben Suárez-Velasco6 Novam y Vita, Guadalajara, Jalisco, Mexico
,
Leopoldo Baiza-Duran7 Clinical Research Department, Laboratorios Sophia, SA de CV, Zapopan, Jalisco, Mexico
,
Oscar Olvera-Montaño7 Clinical Research Department, Laboratorios Sophia, SA de CV, Zapopan, Jalisco, MexicoORCID Iconhttps://orcid.org/0000-0003-2717-349X
ORCID Icon &
Patricia Muñoz-Villegas7 Clinical Research Department, Laboratorios Sophia, SA de CV, Zapopan, Jalisco, MexicoCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7559-1218
ORCID Icon show all
Pages 781-787 | Published online: 02 May 2019

References

  • Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. Aaps J. 2008;10(2):229–241. doi:10.1208/s12248-008-9024-9
  • Cable M. Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at single site. Clin Ophthalmol. 2012;6:997–1004. doi:10.2147/OPTH.S32179
  • Bradley JC, Yang W, Bradley RH, Reid TW, Schwab IR. The science of pterygia. Br J Ophthalmol. 2010;94:815–820. doi:10.1136/bjo.2008.151852
  • Karahan N, Baspinar S, Ciris M, Baydar CL, Kapucuoglu N. Cyclooxygenase-2 expression in primary and recurrent pterygium. Indian J Ophthalmol. 2008;56(4):279–283.
  • Kim AJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Major review. Surv Ophthalmol. 2010;55:108–133. doi:10.1016/j.survophthal.2009.07.005
  • Palacio C, Fernández de OL, Bustos FR, et al. Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population. Clin Ophthalmol. 2016;10:233–237. doi:10.2147/OPTH.S93530
  • Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10:282–288.
  • Che Azemin MZ, Mohd Tamrin MI, Hilmi MT, et al. Inter-grader reliability of supervised pterygium redness grading system. Adv Sci Lett. 2016;22(10):2885–2888. doi:10.1166/asl.2016.7125
  • Che Azemin MZ, Hilmi MR, Mohd Tamrin MI, et al. Fibrovascular redness grading using Gaussian process regression with radial basis function kernel. Biomedical Engineering and Sciences (IECBES). 2014 IEEE Conference on Biomedical Engineering and Sciences (IECBES); 2014; Kuala Lumpur; 113–116. doi:10.1109/IECBES.2014.7047467
  • Hilmi MR, Che Azemin MZ, Mohd Kamal K, et al. Prediction of changes in visual acuity and contrast sensitivity function by tissue redness after pterygium surgery. Current Eye Res. 2017;42:852–856. doi:10.1080/02713683.2016.1250277
  • Fallacara A, Vertuani S, Panozzo G, Pecorelli A, Valacchi G, Manfredini S. Novel artificial tears containing cross-linked hyaluronic acid: an invitro re-epithelization study. Molecules. 2017;22(12):2104. doi:10.3390/molecules22122104
  • You IC, Li Y, Jin R, Ahn M, Choi W, Yoon KC. Comparison of 0.1%, 0.18%, and 0.3% hyaluronic acid eye drops in the treatment of experimental dry eye. J Ocul Pharm Ther. 2018;34(8):557–564. doi:10.1089/jop.2018.0032
  • Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS. A randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eye. J Ocul Pharm Ther. 2017;33(2):66–72. doi:10.1089/jop.2016.0086
  • Robert P-Y, Cochener B, Amrane M, et al. Efficacy and safety of cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. Eur J Ophthalmol. 2016;26(6):546–555. doi:10.5301/ejo.5000830
  • Hwang HS, Sung Y-M, Lee WS, Kim EC. Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops. Cornea. 2014;33(9):935–941. doi:10.1097/ICO.0000000000000213
  • Aragona P, Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops off different osmolarity for the treatment of dry eye in Sjögren‘s syndrome patients. Br J Ophthalmol. 2002;86:879–884.
  • Johnston SC, Williams PB, Sheppard JD. A comprehensive system for pterygium classification. IOVS. 2004;45:2940.
  • Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615–621.
  • Ozgurhan EB, Kara N, Bozkurt E, et al. Effect of fluoremethalone/tetrahydrozoline fixed combination on conjuctival autograft morphology after primary pterygium excision. Biomed Res Int. 2013;2013(481843):8. doi:10.1155/2013/481843
  • Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use. Drug Saf. 2002;25(4):233–250. doi:10.2165/00002018-200225040-00002

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.